Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCCA Conditioning for Auto-HSCT in Lymphoma and Leukemia
NCT06060782Phase 1Recruiting
- Sponsor
- The Fifth Affiliated Hospital of Sun Yat-sen University
- Start
- Mar 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of thiotepa, cyclophosphamide, cladribine and cytarabine in Burkitt lymphoma (BL), lymphoblastic lymphoma (LL) and acute lymphoblastic leukemia (ALL), sponsored by The Fifth Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Recurrence-Free Survival Rate at 3 years. Started Mar 2024; status: recruiting.
02
Drugs
thiotepacyclophosphamidecladribinecytarabine
03
Conditions
Burkitt lymphoma (BL)lymphoblastic lymphoma (LL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06060782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06060782.